Point72 Europe (London) LLP Monte Rosa Therapeutics, Inc. Transaction History
Point72 Europe (London) LLP
- $1.97 Billion
- Q3 2025
A detailed history of Point72 Europe (London) LLP transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 591 shares of GLUE stock, worth $8,486. This represents 0.0% of its overall portfolio holdings.
Number of Shares
591Holding current value
$8,486% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GLUE
# of Institutions
133Shares Held
55.7MCall Options Held
159KPut Options Held
269K-
Nea Management Company, LLC Timonium, MD7.69MShares$110 Million3.56% of portfolio
-
Bvf Inc San Francisco, CA5.66MShares$81.3 Million2.27% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$81.2 Million68.34% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$70.6 Million0.3% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.64MShares$66.6 Million0.0% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $671M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...